Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 10/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176710 | 0.97 | CNR2 (0.42) | ALDH1A1POLBCNR2EPHX1CNR1 | |
| SCHEMBL176833 | 0.90 | POLB (0.43) | POLBCNR2CNR1NPC1RAB9A | |
| SCHEMBL176743 | 0.90 | EPHX2 (0.47) | CNR2CNR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL176414 | 0.89 | NPC1 (0.44) | POLBCNR2CNR1NPC1RAB9A | |
| SCHEMBL176941 | 0.87 | NPC1 (0.41) | POLBCNR2CNR1NPC1RAB9A | |
| SCHEMBL176650 | 0.87 | EPHX2 (0.45) | CNR2CNR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL176581 | 0.86 | CNR2 (0.41) | ALDH1A1CNR2CNR1SMN1; SMN2 | |
| SCHEMBL176400 | 0.86 | ALDH1A1 (0.44) | ALDH1A1POLBCNR2EPHX1CNR1 | |
| SCHEMBL176795 | 0.86 | POLB (0.42) | ALDH1A1POLBCNR2CNR1SMN1; SMN2 | |
| SCHEMBL3466283 | 0.86 | TBXA2R (0.39) | ALDH1A1POLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | disclosed |
| WO-2008115705-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | WO | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007038036-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | CNR2, CNR1, FAAH | ALDH1A1 1422/4885POLB 4527/4885CNR2 1/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | ALDH1A1 1422/4885POLB 4527/4885CNR2 1/4885 |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | ALDH1A1 1422/4885POLB 4527/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.